Idiopathic Pulmonary Fibrosis Treatment Market Worth USD 4.2 billion by 2026
24 juil. 2019 08h46 HE
|
Acumen Research and Consulting
LOS ANGELES, July 24, 2019 (GLOBE NEWSWIRE) -- Acumen Research and Consulting, Recently Published Report On “Idiopathic Pulmonary Fibrosis Treatment Market (By Drug Class: Tyrosine Inhibitors, MAPK...
Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56% Outperforming USFDA Approved Treatments Nintedanib and Pirfenidone
03 juil. 2019 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 03, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference
18 juin 2019 16h05 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., June 18, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics Announces First Quarter 2019 Financial Results and Recent Business Developments
13 juin 2019 16h09 HE
|
Trevi Therapeutics
Raised $70 Million in Gross Proceeds from Initial Public Offering and Concurrent Private Placement Initiated Phase 2 Clinical Trial for Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis...
Algernon Pharmaceuticals Expands Its Research Program to Include Idiopathic Pulmonary Fibrosis
25 févr. 2019 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
FibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat Patients With Idiopathic Pulmonary Fibrosis
11 mars 2016 08h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, March 11, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (FibroGen) announced today that the European Respiratory Journal (“ERJ”) published on-line a manuscript...
Coalition for Pulmonary Fibrosis to Cease Operations
19 nov. 2015 10h25 HE
|
Coalition for Pulmonary Fibrosis (CPF)
CULVER CITY, Calif., Nov. 19, 2015 (GLOBE NEWSWIRE) -- "Never doubt that a small group of thoughtful, committed, citizens can change the world. Indeed, it is the only thing that ever has." -- Margaret...
SPORTS RADIO HOST, COMMERCIAL BANK VP, ST. JUDE, UTHSC DOCTORS, TEMPLE ISRAEL RABBI TO SPEAK AT BOTANIC GARDEN CEREMONY
16 juil. 2015 14h29 HE
|
Coalition for Pulmonary Fibrosis (CPF)
MEMPHIS, Tenn., July 16, 2015 (GLOBE NEWSWIRE) -- A deadly lung disease most have never heard of is lurking in the community and threatening the lives of some well-known Memphians as it has claimed...
CPF Celebrates Historic Year of Progress in Pulmonary Fibrosis
30 déc. 2014 14h05 HE
|
Coalition for Pulmonary Fibrosis (CPF)
CULVER CITY, Calif., Dec. 30, 2014 (GLOBE NEWSWIRE) -- The Coalition for Pulmonary Fibrosis (CPF) played an important role in much of the year's successes in Pulmonary Fibrosis (PF), helping to make...
CORRECTION - Two FDA Approvals on Same Day Renew Hope for Pulmonary Fibrosis Community
16 oct. 2014 17h19 HE
|
Coalition for Pulmonary Fibrosis (CPF)
CULVER CITY, CALIF., Oct. 16, 2014 (GLOBE NEWSWIRE) -- In its press release dated October 16, 2014 at 10:46 AM EST with the headline "Two FDA Approvals on Same Day Renew Hope for Pulmonary Fibrosis...